Evidence map›Paper›PMID 39949960›Full record

ArticleiScience2025

Oxidative stress induced protein aggregation via GGCT produced pyroglutamic acid in drug resistant glioblastoma.

Deanna Tiek, Xiao Song, Xiaozhou Yu, Runxin Wu, Rebeca Iglesia, Alicia Catezone, Katy McCortney, Jordain Walshon, Craig Horbinski, Pouya Jamshidi and 5 more

Abstract read
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Deanna TiekThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Xiao SongThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Xiaozhou YuThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Runxin WuThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Rebeca IglesiaThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Alicia CatezoneDepartments of Pathology and Neurological Surgery, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Katy McCortneyDepartments of Pathology and Neurological Surgery, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Jordain WalshonDepartments of Pathology and Neurological Surgery, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Craig HorbinskiDepartments of Pathology and Neurological Surgery, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Pouya JamshidiDepartment of Pathology, Northwestern University Feinberg School of Medicine, The Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Chicago, IL 60611, USA.
Rudolph CastellaniDepartment of Pathology, Northwestern University Feinberg School of Medicine, The Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Chicago, IL 60611, USA.
Robert VassarThe Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, The Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Chicago, IL 60611, USA.
Jason MiskaDepartment of Neurosurgery, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Bo HuThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Shi-Yuan ChengThe Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR · 2021 to 2026
$26.3M
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hui Zhang · 2018 to 2026
$21.4M
Targeting RNA Splicing in GliomaR01NS125318 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Shi-Yuan Cheng · 2022 to 2026
$2.4M
Role of Protein Methylation in Cell Mitosis and GlioblastomaR01NS115403 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHENG, SHI-YUAN · 2020 to 2024
$2.1M
Therapeutic Targeting in EGFR-amplified GlioblastomaR01NS133160 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Shi-Yuan Cheng · 2024 to 2026
$1.4M
Ferroptosis in drug resistant gliomaR00CA279896 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Deanna Marie Tiek · 2025 to 2026
$498k
Cysteine Depletion-induced Ferroptosis as a Therapeutic Vulnerability iR21NS126810 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHENG, SHI-YUAN · 2022 to 2023
$440k
Targeting ATG4B to Treat GlioblastomaR21NS122375 · NINDS · NORTHWESTERN UNIVERSITY · PI CHENG, SHI-YUAN, SCHEIDT, KARL A · 2022 to 2023
$423k
Novel relationships of splicing factors in temozolomide-resistant glioblastomaK00CA234799 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TIEK, DEANNA MARIE · 2020 to 2023
$369k
Ferroptosis in drug resistant gliomaK99CA279896 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI TIEK, DEANNA MARIE · 2023 to 2024
$257k
Novel relationships of splicing factors in temozolomide-resistant glioblastomaF99CA234799 · NCI · GEORGETOWN UNIVERSITY · PI TIEK, DEANNA MARIE · 2018 to 2018
$34k
NCI NIH HHS F99 CA234799NCI NIH HHS K00 CA234799NCI NIH HHS K99 CA279896NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA221747NCI NIH HHS R00 CA279896NIA NIH HHS P30 AG072977NINDS NIH HHS R01 NS115403NINDS NIH HHS R01 NS125318NINDS NIH HHS R01 NS133160NINDS NIH HHS R21 NS122375NINDS NIH HHS R21 NS126810
6 · The paper itself

Abstract

Drug resistance is a major barrier to cancer therapies and remains poorly understood. Recently, non-mutational mechanisms of drug resistance have been proposed where a more plastic metabolic response can play a major role. Here, we show that upon drug resistance, glioblastoma (GBM) cells have increased oxidative stress, mitochondria function, and protein aggregation. Gamma (γ)-glutamylcyclotranserase (GGCT), an enzyme in the γ-glutamyl cycle for glutathione production, located on chromosome 7 which is commonly amplified in GBM is also increased upon resistance. We further observe that the byproduct of GGCT-pyroglutamic acid-can bind aggregating proteins and that genetic and pharmacological inhibition of GGCT prevents protein aggregation. Finally, we found increased protein aggregation, GGCT expression, and pyroglutamic acid staining in recurrent GBM patient samples, adjacent non-tumor brain, and Alzheimer's brains. These findings suggest a new pathway for protein aggregation within drug resistant brain cancer that should be further studied in other brain disorders.

Indexed as

Biological sciencesCancerMolecular neuroscienceNeuroscience

Identifiers

PMID39949960
PMCPMC11821397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.